ATE401333T1 - 1-oxa-3,9-diazaspiroc5.5üundecan-2-onderivate und deren verwendung als antagonisten des neurokininrezeptors - Google Patents
1-oxa-3,9-diazaspiroc5.5üundecan-2-onderivate und deren verwendung als antagonisten des neurokininrezeptorsInfo
- Publication number
- ATE401333T1 ATE401333T1 AT02742943T AT02742943T ATE401333T1 AT E401333 T1 ATE401333 T1 AT E401333T1 AT 02742943 T AT02742943 T AT 02742943T AT 02742943 T AT02742943 T AT 02742943T AT E401333 T1 ATE401333 T1 AT E401333T1
- Authority
- AT
- Austria
- Prior art keywords
- oxa
- derivatives
- receptor antagonists
- neurokinin receptor
- neurokinin
- Prior art date
Links
- 102000009493 Neurokinin receptors Human genes 0.000 title 1
- 108050000302 Neurokinin receptors Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01111644 | 2001-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE401333T1 true ATE401333T1 (de) | 2008-08-15 |
Family
ID=8177412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02742943T ATE401333T1 (de) | 2001-05-14 | 2002-05-06 | 1-oxa-3,9-diazaspiroc5.5üundecan-2-onderivate und deren verwendung als antagonisten des neurokininrezeptors |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6599900B2 (https=) |
| EP (1) | EP1390372B1 (https=) |
| JP (1) | JP4056887B2 (https=) |
| KR (1) | KR100618063B1 (https=) |
| CN (1) | CN1264847C (https=) |
| AR (1) | AR033631A1 (https=) |
| AT (1) | ATE401333T1 (https=) |
| AU (1) | AU2002342238B2 (https=) |
| BR (1) | BR0209604A (https=) |
| CA (1) | CA2447329C (https=) |
| DE (1) | DE60227657D1 (https=) |
| DK (1) | DK1390372T3 (https=) |
| ES (1) | ES2310206T3 (https=) |
| MX (1) | MXPA03010321A (https=) |
| PT (1) | PT1390372E (https=) |
| WO (1) | WO2002092604A1 (https=) |
| ZA (1) | ZA200308535B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100863854B1 (ko) | 2004-02-10 | 2008-10-15 | 에프. 호프만-라 로슈 아게 | 케모카인 ｃｃｒ5 수용체 조절제 |
| JP2008531509A (ja) | 2005-02-25 | 2008-08-14 | エフ．ホフマン−ラ ロシュ アーゲー | 医薬品成分の改良された分散性を有する錠剤 |
| KR101355064B1 (ko) * | 2005-03-03 | 2014-01-24 | 얀센 파마슈티카 엔.브이. | 치환된 옥사-디아자-스피로-[5.5]-운데카논 유도체 및뉴로키닌 길항제로서의 이의 용도 |
| ATE478075T1 (de) | 2005-03-08 | 2010-09-15 | Janssen Pharmaceutica Nv | Diazaspiro-ä4,4ü-nonanderivate als neurokinin- (nk1)-antagonisten |
| US7470684B2 (en) * | 2007-01-03 | 2008-12-30 | Hoffmann-La Roche Inc. | Spiropiperidine derivatives as NK3 antagonists |
| WO2008090114A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| JP2010522707A (ja) | 2007-03-29 | 2010-07-08 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ウイルス性複素環化合物 |
| TN2017000544A1 (en) | 2015-07-31 | 2019-04-12 | Pfizer | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors |
| RU2720203C1 (ru) | 2017-01-20 | 2020-04-27 | Пфайзер Инк. | 1,1,1-трифтор-3-гидроксипропан-2-илкарбаматные производные как ингибиторы magl |
| CN110198944A (zh) | 2017-01-23 | 2019-09-03 | 辉瑞大药厂 | 作为单酰基甘油脂肪酶抑制剂的杂环螺环化合物 |
| WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
| WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2131021B (en) * | 1982-11-24 | 1985-12-18 | Erba Farmitalia | Antipsychotic benzoxazines |
| IL111960A (en) * | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| DE69633245T2 (de) * | 1995-09-29 | 2005-09-08 | Eli Lilly And Co., Indianapolis | Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation |
-
2002
- 2002-05-06 CN CNB028094735A patent/CN1264847C/zh not_active Expired - Fee Related
- 2002-05-06 ES ES02742943T patent/ES2310206T3/es not_active Expired - Lifetime
- 2002-05-06 EP EP02742943A patent/EP1390372B1/en not_active Expired - Lifetime
- 2002-05-06 CA CA002447329A patent/CA2447329C/en not_active Expired - Fee Related
- 2002-05-06 AU AU2002342238A patent/AU2002342238B2/en not_active Ceased
- 2002-05-06 WO PCT/EP2002/004935 patent/WO2002092604A1/en not_active Ceased
- 2002-05-06 KR KR1020037014713A patent/KR100618063B1/ko not_active Expired - Fee Related
- 2002-05-06 JP JP2002589488A patent/JP4056887B2/ja not_active Expired - Fee Related
- 2002-05-06 AT AT02742943T patent/ATE401333T1/de not_active IP Right Cessation
- 2002-05-06 PT PT02742943T patent/PT1390372E/pt unknown
- 2002-05-06 DK DK02742943T patent/DK1390372T3/da active
- 2002-05-06 MX MXPA03010321A patent/MXPA03010321A/es active IP Right Grant
- 2002-05-06 BR BR0209604-8A patent/BR0209604A/pt not_active IP Right Cessation
- 2002-05-06 DE DE60227657T patent/DE60227657D1/de not_active Expired - Lifetime
- 2002-05-10 US US10/143,431 patent/US6599900B2/en not_active Expired - Fee Related
- 2002-05-10 AR ARP020101705A patent/AR033631A1/es unknown
-
2003
- 2003-10-31 ZA ZA200308535A patent/ZA200308535B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1507449A (zh) | 2004-06-23 |
| CA2447329C (en) | 2009-07-28 |
| AU2002342238B2 (en) | 2007-01-25 |
| BR0209604A (pt) | 2004-03-23 |
| KR20030094405A (ko) | 2003-12-11 |
| CN1264847C (zh) | 2006-07-19 |
| MXPA03010321A (es) | 2004-02-17 |
| AR033631A1 (es) | 2003-12-26 |
| KR100618063B1 (ko) | 2006-08-30 |
| WO2002092604A1 (en) | 2002-11-21 |
| ZA200308535B (en) | 2005-01-31 |
| DK1390372T3 (da) | 2008-09-15 |
| JP2004534758A (ja) | 2004-11-18 |
| DE60227657D1 (de) | 2008-08-28 |
| EP1390372B1 (en) | 2008-07-16 |
| ES2310206T3 (es) | 2009-01-01 |
| EP1390372A1 (en) | 2004-02-25 |
| PT1390372E (pt) | 2008-08-25 |
| JP4056887B2 (ja) | 2008-03-05 |
| US20030004163A1 (en) | 2003-01-02 |
| US6599900B2 (en) | 2003-07-29 |
| CA2447329A1 (en) | 2002-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60325493D1 (de) | Substituierte 1,4-dipiperidin-4-yl-piperazinderivate und deren verwendung als neurokininantagonisten | |
| ATE381565T1 (de) | 1,3,8-triaza-spiro 4,5 decan-4-onderivative als neurokininrezeptorantagonisten | |
| DE50213525D1 (de) | Substituierte 2, 6-diamino-3, 5-dicyano-4-aryl-pyridine und ihre verwendung als adenosinrezeptor selektive liganden | |
| DE50208895D1 (de) | Substituierte 2-thio-3, 5-dicyano-4-aryl-6-aminopyridine und ihre verwendung als adenosinrezeptor-selektive liganden | |
| DE50210986D1 (de) | Substituierte 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre verwendung als adenosinrezeptor-selektive liganden | |
| DE60113719D1 (de) | Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten | |
| DE60201437D1 (de) | 2,6-substituierte chromanderivate und ihre verwendung als beta-3 adrenorezeptor agonisten | |
| DE60336266D1 (de) | Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl-piperazinderivate und deren verwendung als neurokinin antagonisten | |
| DE60106607D1 (de) | Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten | |
| NO20052496D0 (no) | Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter. | |
| DE60114413D1 (de) | Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten | |
| ATE301638T1 (de) | 3-arylindolderivate und deren verwendung als cb2- rezeptoragonisten | |
| DE50204037D1 (de) | Substituierte 1-oxa-2,8-diaza-spiro[4,5]dec-2-en-derivate als arzneimittel gegen schmerz | |
| DE602005011593D1 (de) | Substituierte diazaspiroä5.5üundecanderivate und deren verwendung als neurokininantagonisten | |
| ATE432282T1 (de) | 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten | |
| ATE401333T1 (de) | 1-oxa-3,9-diazaspiroc5.5üundecan-2-onderivate und deren verwendung als antagonisten des neurokininrezeptors | |
| DE602005007002D1 (de) | Substituierte 4-alkyl- und 4-alkanoylpiperidinderivate und deren verwendung als neurokininantagonisten | |
| DE60305026D1 (de) | 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten | |
| ATE353881T1 (de) | 1,4-diazepan-2,5-dion-derivate und deren verwendung als nk-1 rezeptorantagonisten | |
| DE60120711D1 (de) | Arylethene-sulfonamid derivate, deren herstellung und deren verwendung als endothelin-antagonisten | |
| DE50100358D1 (de) | Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten | |
| ATE361295T1 (de) | Substituierte diketopiperazine und deren verwendung als oxytocynantagonisten | |
| ATE389659T1 (de) | Benzoxazepinderivate und deren verwendung als stimulatoren des ampa-rezeptors | |
| ATE353325T1 (de) | 4-heterocyclylsulfonamidyl-6-methoxy-5-(2-metho y-phenoxy)-2-pyridyl-pyrimidin derivate, deren herstellung und deren verwendung als endothelin rezeptor antagonisten | |
| ATE484503T1 (de) | 2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1390372 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |